• Leadership and Structure
• Corporate Governance
• Public Policy
  • Access and Affordability
    • Patient Assistance Programs
    • Policies Limiting Choice of Prescription Drugs
    • Medicare Prescription Drug Benefit
    • Advertising and Promotion
      • More About Advertising and Promotion
  • Pricing and Value
  • Health Care Reform
  • Resources
  • Pat the Pill
• History
• Accolades

Pfizer Public Policy: More about Advertising and Promotion

Prescription Drug Advertising: Empowering Consumers Through Information (89 KB), Pfizer Inc, Economic Realities in Health Care Policy, 2001; Vol. 2, Iss. 1

While much of the debate in broadcast media has focused on the potential impact of advertising on drug prices-and the authors present here clear evidence that such a connection does not exist-few have focused on the empowering benefits to consumers provided by DTC ads. This issue of Economic Realities in Health Care Policy addresses both the economic and consumer issues head-on.

• Download the PDF

The Impact of Direct-to-Consumer Advertising
FDA Consumer magazine, March-April 2003

When it comes to advertising prescription drugs on radio and television and in magazines, doctors say that for the most part the ads help people more than hurt them, according to this article from FDA Consumer magazine, which reviews results from an FDA survey of 500 physicians released in Jan. 2003.

• Learn more

Pharmaceutical Marketing and Promotion: Creating Access to Innovation Pfizer Inc, Economic Realities in Health Care Policy, 2003; Vol. 3, Iss. 1

The promotion and marketing of pharmaceutical products continues to be a controversial topic in the current health care debate and is the subject of this issue of Economic Realities in Health Care Policy. A previous issue in this series focused exclusively on the economics of direct-to-consumer advertising, whereas here the authors present data and evidence on a broader terrain with a particular focus on the potentially important role marketing and promotion play in enabling the flow of information that is quite difficult to convey to patients and physicians.

• Download the PDF

Risk Information in Print Advertisements (216 KB), Pfizer comments to the US Food and Drug Administration in the matter of Disclosing Risk Information in Consumer-Directed Print Advertisements, May 7, 2004

In its comments to the FDA on Risk Information in Print Advertisements, Pfizer urges the FDA to articulate the objectives and reform the technique of its approach to DTC risk disclosures. In Pfizer's view, the public health would be well served if FDA concluded that consumer-directed risk disclosures should (1) help a consumer to reasonably discuss a drug's benefits and risks with his or her doctor, and (2) prompt the consumer to alert the doctor to personal health information that should be factored into the treatment decision. By explicitly adopting this two-pronged goal, Pfizer suggests the FDA would position itself well for crafting sustainable disclosure regulations.

• Download the PDF

Direct to Consumer Promotional Communications (293 KB), Pfizer comments to the US Food and Drug Administration in the matter of Consumer-Directed Promotion, December 1, 2003

In its comments to the FDA on Consumer Promotional Communications, Pfizer states that the agency's current DTC rules and policies are working as they should: the regulations foster messages that motivate and enable consumers to engage in thoughtful, constructive dialogue with doctors about their health conditions and treatment options. Pfizer concludes that FDA would be ill-advised to embark on any precipitous change to the current regime without first having confidence, grounded in solid research, that any such revision would not threaten these substantial public health interests.

• Download the PDF

DTC Benefits Supported By a Strong Data Record

This two-pager traces the impact of DTC advertising along the patient treatment path, highlighting how DTC enhances the health care experience from both the consumer and the physician perspective.

• Download the PDF

Last Updated September 2007

If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.

A

B-D

E-H

I-N

O-P

R-Z

A-B

C

D-E

F-L

M-P

R-U

V-Z